

TRIVALENT THERAPEUTICS INC.

Non-Confidential Licensing Brief

Retatrutide + Naltrexone — combination method for Alcohol Use Disorder

The opportunity in one line: a specific, pending intellectual-property position on a dual-pathway combination for Alcohol Use Disorder (AUD) — pairing a GLP-1/GIP/glucagon tri-agonist (retatrutide) with the approved opioid antagonist naltrexone — available for option or license to a partner positioned to develop it.

The asset

- **U.S. Patent Application No. 19/705,839** (filed June 2026; pending, unexamined): method-of-use, composition, and kit claims directed to the retatrutide + naltrexone combination for AUD.
- **Mechanistic rationale:** naltrexone blocks opioid-mediated reward; incretin agonism attenuates the interoceptive/metabolic drivers of alcohol use. Retatrutide's glucagon-receptor activity is the basis for a differentiated, tri-agonist-specific position.
- **Defined path to specific claims:** dose-ratio, fixed-dose co-formulation, titration, and responder-subpopulation (e.g., OPRM1) embodiments, supportable by a staged preclinical package (available under CDA).

Why now

- AUD is a large, under-treated indication with no major new pharmacotherapy approval since 2006, and mounting human evidence that GLP-1-class agents reduce alcohol use.
- Incretin-for-AUD is advancing clinically (e.g., GLP-1/GIP and GLP-1/glucagon programs in Phase 2–3). A defined combination position is timely for a partner building in this space.

What this is — and what it is not (stated plainly)

What it is	What it is not
● A specific, pending combination IP position in a timely indication. ● A blocking/clearing position a developer can license to secure freedom to operate on the combination. ● Extensible to specific formulation / dose-ratio / responder claims with data.	● Not a granted patent — pending and unexamined; scope uncertain. ● Not composition-of-matter on retatrutide (an Eli Lilly compound); this is a method-of-use position. ● Not clinically validated — no combination data yet; closest prior art (a Novo Nordisk GLP-1 + naltrexone application) is being addressed with counsel.

Status & what we're seeking

- **Status:** independent patentability opinion in progress; claim set being tailored; a staged preclinical data plan is defined.
- **Seeking:** early option, evaluation, or licensing discussions with a partner able to develop or clear the combination. Detailed IP and data plan available under a confidentiality agreement.

Contact: Gabriel Hernandez, Founder — Trivalent Therapeutics Inc., 8 The Green, Suite A, Dover, DE 19901 — gabriel.a.hernandez@outlook.com

This brief is for informational purposes only. It is not an offer to sell or a solicitation to buy any security, and not an offer of a definitive license. The patent application is pending; no patent rights have been granted. Forward-looking statements about mechanism and potential may prove incorrect.